The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 14, 2025

Filed:

Dec. 12, 2022
Applicant:

Arvinas Operations, Inc., New Haven, CT (US);

Inventors:

Andrew P. Crew, Chester, CT (US);

Michael Berlin, Flemington, NJ (US);

Keith R. Hornberger, Southbury, CT (US);

Lawrence B. Snyder, Killingworth, CT (US);

Jing Wang, Milford, CT (US);

Yimin Qian, Plainsboro, NJ (US);

Hanqing Dong, Madison, CT (US);

Kurt Zimmermann, Durham, CT (US);

Assignee:

Arvinas Operations, Inc., New Haven, CT (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 401/14 (2006.01); A61P 35/02 (2006.01); C07D 417/14 (2006.01); C07D 471/04 (2006.01); C07D 471/10 (2006.01); C07D 487/04 (2006.01); C07D 495/14 (2006.01); C07D 498/04 (2006.01);
U.S. Cl.
CPC ...
C07D 401/14 (2013.01); A61P 35/02 (2018.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01); C07D 471/10 (2013.01); C07D 487/04 (2013.01); C07D 495/14 (2013.01); C07D 498/04 (2013.01);
Abstract

The description relates to cereblon E3 ligase binding compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present disclosure. In particular, the description provides compounds, which contain on one end a ligand which binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.


Find Patent Forward Citations

Loading…